Grants(10)

A Phase 1 Study to Evaluate the Efficacy and Safety Of AB-101, an Allogeneic Cord Blood Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III
Active·2024·$0 / $141.8K·
External
Co-Investigator (COI)
cell therapy, immunotherapy, cancer treatment, clinical trial
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tai-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pom
Active·2023·$546.3K·
External
Principal Investigator (PI)
clinical trials, immunotherapy, multiple myeloma, combination therapy, drug development
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Active·2023·$464.7K·
External
Principal Investigator (PI)
cell therapy, cancer treatment, crispr, lymphoma, clinical trial
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritnib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/r Amil) With FMS-like Tyrosine Mutation (FLT3 mu
Active·2023·$0 / $116.3K·
External
Co-Investigator (COI)
acute myeloid leukemia, mutation, combination therapy, treatment
A Phase 1b/2, Open Label Umbrella Study Of Elranatamab (PF- 06863135), A B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, In Combination With Other Anti-Cancer Treatments In Participants With
2023·$0 / $1.2M·
External
Co-Investigator (COI)
cancer immunotherapy, bispecific antibodies, clinical trials, bcma targeted therapy, combination therapy

Page 1 of 2

People

Profile

Muhammad Husnain

Collaboration(20)

Bonnie LaFleur

Denise Roe

Megha Padi

Richard Simpson

Emmanuel Katsanis

Grants(10)

A Phase 1 Study to Evaluate the Efficacy and Safety Of AB-101, an Allogeneic Cord Blood Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III

A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tai-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pom

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritnib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/r Amil) With FMS-like Tyrosine Mutation (FLT3 mu

A Phase 1b/2, Open Label Umbrella Study Of Elranatamab (PF- 06863135), A B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, In Combination With Other Anti-Cancer Treatments In Participants With

Publications(14)

A Comparative Analysis of Clinical Features of Diabetes Mellitus Type 2 With Respect to Duration of Diabetes

A Case of Persistent Pasteurella multocida Cellulitis Complicated With Large Endocarditis Vegetation

A Comprehensive Case Report on Familial Multiple Lipomatosis

A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma

Developing lifestyle intervention program for pre-hypertensive patients; consensus building using a modified Delphi approach

Comparable Efficacy of Oral Bendamustine versus Intravenous Administration in Treating Hematologic Malignancies

Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy

Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis

Refractory Pure Red Blood Cell Aplasia Secondary to Major ABO-Incompatible Allogeneic Stem Cell Transplantation Successfully Treated With Daratumumab

Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects